gefitinib has been researched along with epidermal growth factor in 220 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 151 (68.64) | 29.6817 |
| 2010's | 58 (26.36) | 24.3611 |
| 2020's | 11 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A | 1 |
| Norman, P | 1 |
| Ahmad, T; Anderson, NG; Bundred, NJ; Chan, K; Dobson, R | 1 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Hirata, A; Kometani, T; Kuwano, M; Kuwano, T; Naito, S; Ogawa, S; Ono, M | 1 |
| Baselga, J | 2 |
| Bundred, N; Gilmore, AP; Korsmeyer, SJ; O'Hare, MJ; Ranger, AM; Streuli, CH; Valentijn, AJ; Wakeling, A; Wang, P | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Morris, C | 1 |
| Wilkinson, E | 1 |
| Couzin, J | 1 |
| Castro, M | 1 |
| Hynes, NE; Motoyama, AB | 1 |
| Cullinane, C; Hagekyriakou, J; McArthur, GA; Solomon, B; Stacker, SA; Trivett, MK | 1 |
| Dummer, R; Follath, F; Jacky, E; Trojan, A | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Lavelle, F | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Marronaro, A; Vicentini, C | 1 |
| Almqvist, Y; Carlsson, J; Sundberg, AL; Tolmachev, V | 1 |
| Arteaga, CL; Johnson, DH | 1 |
| Averbuch, S; Baselga, J; Dong, RP; Douillard, JY; Eek, R; Feyereislova, A; Fukuoka, M; Giaccone, G; Horai, T; Kudoh, S; Macleod, A; Nakagawa, K; Nishiwaki, Y; Noda, K; Rischin, D; Smit, E; Takata, I; Tamura, T; Vansteenkiste, J; Yano, S | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Androulakis, N; Bozionelou, V; Georgoulias, V; Kouroussis, C; Mavroudis, D; Pallis, AG; Souglakos, J; Vlachonikolis, IG | 1 |
| Fujii, K; Kihara, N; Kohrogi, H; Matsumoto, M; Okamoto, I; Suga, M; Terasaki, Y | 1 |
| Douglass, EC | 1 |
| Aono, Y; Azuma, M; Kanematsu, T; Miki, T; Sone, S; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D | 1 |
| Ardizzoni, A; Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L; Gridelli, C; Maione, P; Santoro, A; Soto-Parra, H; Tiseo, M | 1 |
| Behnken, D; Govindan, R; McLeod, H; Read, W | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigue, CM; Rodrigues, S; Thim, L; Westley, BR | 1 |
| Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Magné, N; Milano, G; Renée, N; Tiffon, C | 1 |
| Almqvist, Y; Blomquist, E; Carlsson, J; Gedda, L; Jensen, HJ; Orlova, A; Sundberg, AL; Tolmachev, V | 1 |
| Gemma, A; Kudoh, S; Yoshimura, A | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Endo, H; Hida, T; Masuda, A; Mitsudomi, T; Nakagawa, T; Sugiura, T; Suzuki, T; Takahashi, T; Yatabe, Y | 1 |
| Basso, A; Moasser, MM; She, QB; Solit, D | 1 |
| Campiglio, M; Fumagalli, M; Gianni, L; Locatelli, A; Ménard, S; Normanno, N; Olgiati, C; Somenzi, G; Viganò, L | 1 |
| Blackledge, G | 1 |
| Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ | 1 |
| Dong, RP; Yamaguchi, M; Yano, S | 1 |
| Natale, RB | 1 |
| Sandler, AB | 1 |
| Schiller, JH | 1 |
| Khuri, FR | 1 |
| Ambrad, AA; Carey, S; Falsey, R; Glanzberg, H; Kislin, K; Martinez, JD; Meuillet, EJ; Patel, J; Stea, B | 1 |
| Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Kurebayashi, J; Okubo, S; Sonoo, H; Yamamoto, Y | 1 |
| Vansteenkiste, J | 1 |
| Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z | 1 |
| Haraguchi, N; Kikuchi, N; Kodama, T; Satoh, H; Sekizawa, K | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Ochs, JS | 1 |
| Averbuch, S; Kelly, K | 1 |
| Azzoli, C; Ben-Porat, L; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Memoli, N; Miller, VA; Pao, W; Patel, J; Pizzo, B; Rizvi, N; Rusch, V; Shah, N; Tyson, L; Venkatraman, E; Zakowski, M | 1 |
| Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ | 1 |
| Ranson, M; Wardell, S | 1 |
| Fujii, T; Hirata, A; Kinoshita, H; Kometani, T; Kuwano, M; Miyagawa, M; Ono, M; Ueda, S | 1 |
| Lazarowicz, HP; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY | 1 |
| Bell, DW; Brannigan, BW; Christiani, DC; Gurubhagavatula, S; Haber, DA; Haluska, FG; Harris, PL; Haserlat, SM; Louis, DN; Lynch, TJ; Okimoto, RA; Settleman, J; Sordella, R; Supko, JG | 1 |
| Siegfried, JM; Stabile, LP | 1 |
| Baker, M | 1 |
| Gazdar, AF; Herz, J; Minna, JD; Sprang, SR | 1 |
| Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA | 1 |
| Hayes, DF | 1 |
| Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H | 1 |
| Giaccone, G | 1 |
| Aderka, D; Levitt, ML; Pfeffer, MR | 1 |
| Futreal, PA; Stratton, MR | 1 |
| Hirata, A; Izumi, K; Kuwano, M; Naito, S; Ono, M; Uehara, H | 1 |
| Baldi, E; Bonaccorsi, L; Forti, G; Marchiani, S; Muratori, M | 1 |
| Alimonti, A; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Martinelli, E; Matar, P; Milella, M; Papaldo, P | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G | 1 |
| Pizzo, B | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT | 1 |
| Senior, K | 1 |
| Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC | 1 |
| Baselga, J; Fukuoka, M; Herbst, RS | 1 |
| Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP | 1 |
| Aoe, M; Doihara, H; Hara, H; Ishibe, Y; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Teramoto, J; Yoshitomi, S | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Cadranel, J; Madelaine, J; Zalcman, G | 1 |
| Blandin, S; Gérinière, L; Girard, N; Perrot, E; Souquet, PJ | 1 |
| Barnard, GF; Inoue, H; Ishii, H; Ishikawa, K; Mimori, K; Mori, M; Ohta, M; Utsunomiya, T; Yamashita, K; Yoshinaga, K | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Hoang-Xuan, K; Sanson, M; Thillet, J | 1 |
| Hansen, FD; Nexø, E; Sørensen, BS; Tørring, N; Ørntoft, TF | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 1 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Choo, MK; Koizumi, K; Matsuo, M; Saiki, I; Sakurai, H; Ueno, Y | 1 |
| Bell, DW; Haber, DA; Louis, DN; Riemenschneider, MJ | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L | 1 |
| Batra, SK; Depreux, P; Hénichart, JP; Lin, MF; Mimeault, M; Moniaux, N; Moore, E | 1 |
| Eicke, N; Emons, G; Gründker, C; Günthert, AR; Läsche, J; Olota, A | 1 |
| Greulich, H; Griffin, JD; Jänne, PA; Jiang, J; Meyerson, M; Sellers, WR | 1 |
| Chen, YR; Chen, YT; Fu, YN; Hu, SF; Huang, SF; Lin, CH; Tsai, SF; Yang, ST | 1 |
| Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH | 1 |
| Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 1 |
| Abdallah, R; Albitar, L; Laidler, LL; Leslie, KK | 1 |
| Bozec, A; Ciccolini, J; Fanciullino, R; Fischel, JL; Formento, P; Milano, G; Murraciole, X; Padovani, L | 1 |
| Akizawa, T; Hatamura, I; Negi, S; Orita, H; Saji, F; Sakaguchi, T; Shibata, M; Shiizaki, K | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S | 1 |
| Choi, SH; Lemmon, MA; Mendrola, JM | 1 |
| Carotenuto, A; Cito, L; D'Alessio, A; De Luca, A; Guzzo, A; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM | 1 |
| Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O | 1 |
| Memon, AA; Nexo, E; Sorensen, SB | 1 |
| Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J; Su, ZZ | 1 |
| Nexo, E; Ornskov, D; Sorensen, BS | 1 |
| Bonn, GK; Huber, LA; Peränen, J; Schiefermeier, N; Skvortsov, S; Stasyk, T; Zwierzina, H | 1 |
| Foster, PA; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Bereczky, B; Nishimura, Y; Ono, M | 1 |
| Furukawa, M; Goya, S; Greene, MI; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Nagatomo, I; Osaki, T; Tachibana, I; Takahashi, R; Takeda, Y; Yamadori, T; Yoneda, T; Yoshida, M; Yoshimura, M | 1 |
| Arpino, G; Bharwani, L; De Placido, S; Gutierrez, C; Massarweh, S; Osborne, CK; Rimawi, M; Schiff, R; Weiss, H | 1 |
| Ang, BK; Chen, Y; Choong, LY; Druker, BJ; Hew, CL; Li, B; Lim, S; Lim, YP; Lin, Q; Low, TY; Ray, RS; Sze, NS; Tan, YL; Toy, W; Wong, CH | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C | 1 |
| Guo, J; Sheng, G; Warner, BW | 1 |
| Aasrum, M; Christoffersen, T; Dajani, OF; Guren, TK; Lilleby, P; Meisdalen, K; Sandnes, D; Thoresen, GH; Tveteraas, IH | 1 |
| Bailey, KE; Cai, Z; Chen, Z; Costantini, DL; Reilly, RM; Scollard, DA; Vallis, KA | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG | 1 |
| Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W | 1 |
| Aoki, H; Ikegame, Y; Inagaki, A; Iwama, T; Kunisada, T; Nakashima, S; Oka, N; Soeda, A; Yoshimura, S | 1 |
| Arlt, D; Korf, U; Laible, M; Löbke, C; Poustka, A; Rappl, C; Ruschhaupt, M; Sahin, O; Sültmann, H; Wiemann, S | 1 |
| Amin, DN; Bielenberg, DR; Heymach, JV; Klagsbrun, M; Lifshits, E | 1 |
| Bereczky, B; Itoh, K; Nishimura, Y; Yoshioka, K | 1 |
| Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D | 1 |
| Castellani, G; Ceccarelli, C; Coppola, D; Francesconi, M; Guidotti, L; Lauriola, M; Martini, D; Mattei, G; Montroni, I; Pezzetti, F; Rosati, G; Ruggeri, A; Santini, D; Solmi, R; Strippoli, P; Taffurelli, M; Ugolini, G; Voltattorni, M; Zanotti, S | 1 |
| Agulnik, M; Brockstein, B; Lacouture, M | 1 |
| Bongarzone, I; Cassinelli, G; Cremona, M; Cuccuru, G; Gorla, L; Lanzi, C; Miccichè, F; Mondellini, P; Pierotti, MA | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Cusano, G; Ferlini, C; Giangaspero, F; Meco, D; Riccardi, A; Riccardi, R; Servidei, T; Zannoni, GF | 1 |
| Allen, CT; Calvo, KR; Chen, Z; Dabir, B; Friedman, J; Morris, JC; Mundinger, GS; Pernas, FG; Saigal, K; Van Waes, C; Winters, ME; Xu, X; Yan, B | 1 |
| Chang, SE; Choe, H; Choi, J; Hong, JP; Lee, SW; Song, JY | 1 |
| Katayama, K; Mitsuhashi, J; Noguchi, K; Shibata, K; Sugimoto, Y | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Fleisher, M; Hu, G; Kang, Y; Lu, X; Massagué, J; Reiss, M; Van Poznak, C; Wang, Q | 1 |
| Kim, YM; Park, SY; Pyo, H | 1 |
| Hata, R; Imagawa-Ishiguro, Y; Ito, S; Kato, Y; Komori, R; Kubota, E; Maehata, Y; Ozawa, S; Ozono, S; Shiiki, N; Taguchi, T; Tsukinoki, K; Tsukuda, M | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Baldi, E; Forti, G; Gelmini, S; Maggi, M; Marchiani, S; Nesi, G; Orlando, C; Paglierani, M; Tamburrino, L | 1 |
| Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K | 1 |
| Jean-Claude, BJ; Rachid, Z; Watt, HL | 1 |
| Markaverich, BM; Rodriguez, M; Shoulars, K; Vijjeswarapu, M | 1 |
| Dennison, G; Foulstone, EJ; Frankow, A; Holly, JM; Jarrett, C; McIntosh, J; Perks, CM; Winters, ZE | 1 |
| Guo, Y; Jiang, X; Li, Z; Wang, G; Xi, Z; Yan, B; Yao, Y | 1 |
| Bellini, P; Favoni, RE; Harvey, BJ; Manente, AG; Moro, L; Mutti, L; Pinton, G; Thomas, W | 1 |
| Katsifis, A; Lin, HQ; Meriaty, H | 1 |
| Andersson, K; Björkelund, H; Gedda, L | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y; Luwor, RB | 1 |
| Cabodi, S; Camacho-Leal, MP; Defilippi, P; Morello, V; Papotti, M; Repetto, D; Sigismund, S; Turco, E; Volante, M | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Andersson, K; Barta, P; Björkelund, H; Gedda, L; Malmqvist, M | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, YR; Chu, CY; Fang, MY; Hsieh, HP; Hsu, JT; Huang, YW; Lien, TW; Lin, WH; Song, JS; Wu, SH; Yen, KJ | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Assiddiq, BF; Chan, SP; Chong, PK; Lim, YP; Tan, KY; Toy, W | 1 |
| Chaumais, MC; De Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Girerd, B; Guignabert, C; Huertas, A; Humbert, M; Lecerf, F; Montani, D; Perros, F; Tu, L | 1 |
| Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D | 1 |
| Dai, X; Du, Y; Feng, Y; Li, X; Liu, J; Wang, H; Xia, L; Zhang, J | 1 |
| Aasrum, M; Christoffersen, T; Dajani, O; Guren, T; Müller, KM; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Lu, C; Mi, LZ; Schürpf, T; Springer, TA; Walz, T | 1 |
| Cho, BC; Lee, JH; Park, JH; Shin, JU | 1 |
| Beer, DG; Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Kohno, T; Miyano, S; Nagasaki, M; Nakata, A; Nomura, M; Saito, A; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yokota, J; Yoshida, R | 1 |
| Dang, NH; Hayashi, Y; Hosono, O; Ichihara, H; Inoue, Y; Iwata, S; Kamiya, K; Katayose, T; Kawasaki, H; Kichikawa, Y; Kondo, S; Morimoto, C; Sakamoto, M; Souta-Kuribara, A; Tanaka, H; Yamada, T; Yamazaki, H | 1 |
| Chen, MS; Chi, CW; Hsu, CC; Huang, YC; Kuo, CD; Lee, HC; Lee, LM; Lee, YC; Liao, JF; Lin, AM; Yang, CH; Yin, PH | 1 |
| Albeck, JG; Brugge, JS; Mills, GB | 1 |
| Chang, SS; Chen, CT; Du, Y; Herbst, R; Hsu, JL; Hsu, MC; Hung, MC; Ko, HW; Wang, YN; Yamaguchi, H | 1 |
| Contini, A; Erne, P; Ferri, N; Frachet, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Frasca, F; Gianì, F; Lotta, S; Messina, RL; Nicolosi, ML; Regalbuto, C; Vella, V; Vigneri, P; Vigneri, R | 1 |
| Eda, T; Iwakura, Y; Mizuno, M; Nagata, K; Namba, H; Nawa, H; Okubo, T; Shibuya, M; Sotoyama, H; Wang, R | 1 |
| He, P; Li, G | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Saya, H; Yoshida, GJ | 1 |
| Jo, U; Kim, YH; Park, JK; Park, KH; Sung, JS; Whang, YM; Won, NH | 1 |
| Gao, M; Ge, CH; Ge, ZQ; Li, CY; Wang, XH; Yang, XM; Yu, M; Zhan, YQ; Zhang, JH | 1 |
| Beaty, BT; Condeelis, JS; Cox, D; Eddy, RJ; Sharma, VP | 1 |
| Beckett, AJ; Clague, MJ; Coulson, JM; Prior, IA; Tang, WYY; Urbé, S | 1 |
| Asbagh, LA; Baietti, MF; Budinska, E; De Vriendt, V; Hoe, N; Imjeti, NS; Jacobs, B; Sablina, A; Singh, S; Steklov, M; Tejpar, S; Vazquez, I; Vecchione, L; Zimmermann, P | 1 |
| Ito, S; Itoh, K; Nishimura, Y; Takiguchi, S | 1 |
| Demehri, FR; Dempsey, PJ; Feng, Y; Freeman, JJ; Teitelbaum, DH | 1 |
| Cao, XJ; Garcia, BA; Kharbanda, A; Runkle, KB; Stypulkowski, E; Wang, W; Witze, ES | 1 |
| Arai, J; Matsumoto, K; Miyazaki, T; Mochinaga, K; Nagasaki, T; Nagayasu, T; Nanashima, A; Tominaga, T; Tsuchiya, T; Tsukamoto, K; Yamasaki, N | 1 |
| Al-Daccak, R; Antonicelli, F; Bastid, J; Bensussan, A; Cure, H; Fabre, J; Fuselier, C; Garbar, C; Giustiniani, J; Merrouche, Y | 1 |
| Allison, JP; Cha, JH; Chan, LC; Chang, SS; Ding, Q; Hortobagyi, GN; Hsu, JL; Hsu, JM; Hung, MC; Khoo, KH; Kim, T; Kuo, CW; Lee, CC; Lee, HH; Li, CW; Lim, SO; Sahin, AA; Wang, Y; Wu, HJ; Wu, Y; Xia, W; Yamaguchi, H; Yao, J; Yu, D | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L | 1 |
| Chen, JK; Dong, G; Dong, Z; Liu, Y; Yao, Q; Zhang, H; Zhang, M; Zhang, W; Zhou, X | 1 |
| Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M | 1 |
| Collard, TJ; Greenhough, A; Gupta, B; Legge, DN; Morgan, RG; Mortensson, E; Williams, AC | 1 |
| Anderson, JC; Bellis, SL; Britain, CM; Holdbrooks, AT; Willey, CD | 1 |
| Szabo, E; von Achenbach, C; Weller, M | 1 |
| Cunha, SI; Jia, M; Souchelnytskyi, S | 1 |
| Chen, H; Chen, X; Shen, J; Wang, Q; Wu, H; Xie, XJ | 1 |
| Ali, R; Brown, W; Davisson, VJ; Purdy, SC; Wendt, MK | 1 |
| Funato, Y; Hasegawa, A; Miki, H; Mori, MX; Mori, Y; Sato, T; Tran, HN; Yamazaki, D | 1 |
| Gou, Q; Hou, Y; Jiang, Y; Shi, J; Xu, H; Xu, Y; Zhang, R; Zhang, W | 1 |
| Golabi, N; Jean-Claude, BJ; Larroque, AL; Peyrard, L; Williams, C | 1 |
| Kim, MS; Kim, SH; Yang, SH | 1 |
| Blandin, AF; Choulier, L; Cruz Da Silva, E; Dedieu, S; Devy, J; Didier, P; Dontenwill, M; Etienne-Selloum, N; Glushonkov, O; Lehmann, M; Mercier, MC; Schneider, C | 1 |
| Brownfoot, F; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Kandel, M; Masci, J; Nguyen, TV; Pritchard, N; Tong, S; Whigham, CA | 1 |
| Carl, P; Choulier, L; Cruz Da Silva, E; Dedieu, S; Lehmann, M; Rondé, P; Schneider, C; Thevenard-Devy, J | 1 |
| Hur, W; Jo, SJ; Li, N; Oh, JH | 1 |
| Bajan, S; Boonyaratanakornkit, V; Hutvagner, G; Kaewjanthong, P; McGowan, E; Sasano, H; Sooksai, S | 1 |
| Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
| Acconcia, F | 1 |
| El Kerdawy, AM; El-Gazzar, YI; El-Subbagh, HI; George, RF; Georgey, HH; Ghaiad, HR; Youssef, KM | 1 |
28 review(s) available for gefitinib and epidermal growth factor
| Article | Year |
|---|---|
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Why the epidermal growth factor receptor? The rationale for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2002 |
The role of EGFR-directed therapy in the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mammary Neoplasms, Experimental; Quinazolines | 2002 |
Development of ZD1839 in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Iressa (gefitinib)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Topics: Epidermal Growth Factor; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Growth Factor | 2003 |
EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, fos; Humans; Ki-67 Antigen; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Molecular targeted agents in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Gene Expression Regulation; Genes, erbB-1; Humans; Quinazolines; Signal Transduction | 2004 |
Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib, a novel, orally administered agent for the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Estrogen receptor pathways in lung cancer.
Topics: Age Factors; Animals; Antineoplastic Agents; Epidermal Growth Factor; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Receptors, Estrogen; Risk Factors; Sex Distribution; Sex Factors; Signal Transduction; Smoking; Survival Rate; United States | 2004 |
The role of gefitinib in lung cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2004 |
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous | 2004 |
New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Patient Education as Topic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib--a novel targeted approach to treating cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Quinazolines | 2004 |
Molecular changes in gliomas.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Epidermal Growth Factor; Gefitinib; Glioma; Humans; Neovascularization, Pathologic; Quinazolines | 2004 |
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines | 2006 |
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha | 2006 |
Targeted therapy in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
11 trial(s) available for gefitinib and epidermal growth factor
| Article | Year |
|---|---|
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2003 |
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Proteins; Cell Division; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Cytoskeletal Proteins; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Trans-Activators; Tumor Suppressor Proteins | 2003 |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Phase II trial of gefitinib in recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis | 2004 |
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis | 2005 |
Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Cross-Over Studies; Epidermal Growth Factor; Gefitinib; Humans; Intubation, Gastrointestinal; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Tablets | 2004 |
Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Blood Vessels; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Prostaglandins; Quinazolines | 2005 |
182 other study(ies) available for gefitinib and epidermal growth factor
| Article | Year |
|---|---|
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured | 2001 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
Topics: Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2001 |
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Movement; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-8; Lymphokines; Male; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Physiologic; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vulvar Neoplasms | 2002 |
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Carrier Proteins; Cell Death; Cell Line; Cell Survival; Cells, Cultured; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Insulin-Like Growth Factor I; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; Mice, Knockout; Phosphatidylinositol 3-Kinases; Pregnancy; Quinazolines; Receptors, Somatomedin; Signal Transduction; Transcriptional Activation | 2002 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
Surprise phase III failure for ZD1839.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
The simpleton's error in drug development.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Design; Drugs, Investigational; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2002 |
BAD: a good therapeutic target?
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Carrier Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured | 2003 |
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
[14th EORTC-NCI-AAACR Symposium on New Molecular Targets and Cancer Therapeutics].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Germany; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Male; Phosphorylation; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine | 2003 |
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
Topics: Astatine; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioma; Humans; Metabolic Clearance Rate; Protein-Tyrosine Kinases; Quinazolines; Radioisotopes; Radiopharmaceuticals | 2003 |
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines | 2003 |
A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Quinazolines; Radiography; Sputum | 2003 |
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Pneumonectomy; Postoperative Care; Quinazolines; Risk Assessment; Sampling Studies; Wound Healing | 2003 |
Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
Topics: Amphiregulin; Animals; Cells, Cultured; Colonic Neoplasms; Dogs; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, src; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Kidney; Mucins; Muscle Proteins; Mutation; Neoplasm Invasiveness; Neuropeptides; Peptides; Phosphatidylinositol 3-Kinases; Proteins; Quinazolines; Receptors, Thromboxane; Signal Transduction; Transforming Growth Factor alpha; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cisplatin; DNA Repair; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2003 |
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
Topics: Antineoplastic Agents; Astatine; Astrocytoma; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Epidermal Growth Factor; Gefitinib; Humans; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2003 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured | 2003 |
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
Topics: Breast Neoplasms; Chromones; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Tumor Cells, Cultured | 2003 |
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2 | 2004 |
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Cerebellum; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Phosphorylation; Placenta; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2004 |
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Signal Transduction; Tumor Cells, Cultured | 2004 |
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin | 2004 |
Response to gefitinib in pericardial effusion due to lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Smoking | 2004 |
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria | 2004 |
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Ubiquitin-Protein Ligases | 2004 |
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
Topics: Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protease Inhibitors; Quinazolines; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2004 |
EGFR inhibitors square off at ASCO.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Industry; Economic Competition; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2004 |
Cancer. A bull's eye for targeted lung cancer therapy.
Topics: Adenocarcinoma; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Japan; Ligands; Lung Neoplasms; Mutation; Phosphorylation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Smoking; Treatment Outcome; United States | 2004 |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Tamoxifen: Dr. Jekyll and Mr. Hyde?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Trastuzumab | 2004 |
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estrogen Receptor Modulators; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transplantation, Heterologous; Up-Regulation | 2004 |
Gefitinib in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results | 2004 |
Cancer: understanding the target.
Topics: Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Endothelial Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; In Situ Nick-End Labeling; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
ERBB2 kinase mutations in lung-cancer tumours.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines | 2004 |
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Type C Phospholipases | 2004 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
[French experience of gefitinib in non-small cell bronchial carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Male; Middle Aged; Palliative Care; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sex Factors; Smoking | 2004 |
Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Nucleus; Colorectal Neoplasms; Cytoplasm; DNA-Binding Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 7; Middle Aged; Phosphorylation; Protein Transport; Quinazolines; Smad4 Protein; Trans-Activators; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
Topics: Amphiregulin; Androgens; Animals; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gefitinib; Gene Expression; Glycoproteins; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha | 2005 |
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation, Missense; Quinazolines; Sequence Deletion; Stromal Cells; Transforming Growth Factor alpha | 2005 |
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Topics: Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Chemotaxis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Laminin; Male; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoinositide Phospholipase C; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Urokinase-Type Plasminogen Activator | 2005 |
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; DNA Damage; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids | 2006 |
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Phosphorylation; Quinazolines; Signal Transduction; Tamoxifen; Triptorelin Pamoate | 2005 |
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Growth Processes; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interleukin-3; Mice; Mutagenesis, Site-Directed; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transfection | 2005 |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chlorocebus aethiops; COS Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Immunoprecipitation; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Tyrosine; Ubiquitin | 2006 |
Single-dose clinical pharmacokinetic studies of gefitinib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fasting; Female; Gefitinib; Humans; Injections, Intravenous; Linear Models; Male; Middle Aged; Quinazolines; Suspensions; Tablets | 2005 |
Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Phosphoproteins; Quinazolines; Signal Transduction | 2005 |
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.
Topics: Blotting, Western; Cell Division; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2005 |
[Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
Topics: Animals; Cell Proliferation; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hyperplasia; Intracellular Signaling Peptides and Proteins; Male; Parathyroid Glands; Parathyroid Hormone; Phosphorus, Dietary; Quinazolines; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Time Factors; Transforming Growth Factor alpha | 2005 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Interleukin-3; Lung Neoplasms; Models, Molecular; Mutation; Phosphorylation; Protein Binding; Quinazolines | 2007 |
AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Flow Cytometry; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Topics: Biomarkers; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Multigene Family; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Urinary Bladder Neoplasms | 2006 |
Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Topics: Adenoviridae; Adenoviridae Infections; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; eIF-2 Kinase; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
Topics: Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Ligands; Quinazolines; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Urinary Bladder Neoplasms | 2006 |
Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics.
Topics: Cell Culture Techniques; Electrophoresis, Gel, Two-Dimensional; Endosomes; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Proteins; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Early Growth Response Protein 1; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2007 |
The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cathepsin D; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lysosomal Membrane Proteins; Lysosomes; Microscopy, Fluorescence; Protein Transport; Qa-SNARE Proteins; Quinazolines; Receptors, Scavenger; Signal Transduction; Transferrin | 2007 |
Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.
Topics: Animals; Binding Sites; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ligands; Mice; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Sequence Deletion; Tyrosine; Ubiquitin | 2007 |
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Trastuzumab | 2007 |
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.
Topics: Amino Acid Sequence; Cell Line, Tumor; Epidermal Growth Factor; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Molecular Sequence Data; Neoplasms; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Serine Endopeptidases; Signal Transduction; Tandem Mass Spectrometry | 2007 |
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Male; Nerve Growth Factor; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkB; Signal Transduction; Time Factors | 2007 |
Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Enterocytes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ileum; Imidazoles; Mitochondria; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Pyridines; Quinazolines; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; Time Factors; Tyrphostins | 2007 |
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cells, Cultured; Culture Media, Serum-Free; Cyclin D; Cyclins; Dinoprostone; DNA; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation; Hepatocytes; Liver Neoplasms; Male; Pertussis Toxin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins | 2008 |
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Topics: Antineoplastic Agents; Cell Compartmentation; Cell Line, Tumor; Cell Nucleus; Electrons; Epidermal Growth Factor; ErbB Receptors; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gefitinib; Humans; Indium Radioisotopes; Pentetic Acid; Phosphorylation; Protein Transport; Quinazolines; Radiopharmaceuticals; Signal Transduction | 2007 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2007 |
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.
Topics: AC133 Antigen; Antigens, CD; Brain Neoplasms; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Peptides; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Stem Cells; Tumor Cells, Cultured; Tyrphostins | 2008 |
Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glutathione Transferase; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Recombinant Fusion Proteins; Reference Standards; Signal Transduction; Trastuzumab; Tumor Cells, Cultured | 2008 |
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Fluorescence; Phosphorylation; Quinazolines; Signal Transduction; Sorting Nexins; Vesicular Transport Proteins | 2008 |
Response of malignant thymoma to erlotinib.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma | 2008 |
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cluster Analysis; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Electron, Scanning; Microvilli; Oligonucleotide Array Sequence Analysis; Quinazolines | 2008 |
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Topics: Animals; Antineoplastic Agents; Carcinoma, Medullary; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oncogene Proteins; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Tyrosine | 2009 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; NF-kappa B; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2009 |
Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction | 2009 |
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
Topics: ADAM Proteins; ADAMTS1 Protein; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; Epidermal Growth Factor; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Matrix Metalloproteinase 1; Mice; Mice, Nude; Osteoblasts; Osteoprotegerin; Protein Kinase Inhibitors; Quinazolines; RANK Ligand; Signal Transduction | 2009 |
Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Topics: Cyclooxygenase 2; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Protein Biosynthesis; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Transcription, Genetic | 2009 |
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemokines, CXC; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mutation; Quinazolines; RNA, Messenger | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Topics: Androgens; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Neuroendocrine Cells; Phosphopyruvate Hydratase; Prostatic Neoplasms; Quinazolines; Receptors, Androgen | 2010 |
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Models, Biological; Mutation; Octreotide; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Time Factors; Transfection | 2010 |
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2010 |
IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.
Topics: Biotinylation; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Fibronectins; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Laminin; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Radioimmunoassay; rho-Associated Kinases | 2010 |
Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Etoposide; Gefitinib; Green Fluorescent Proteins; Humans; Immunoblotting; Microscopy, Immunoelectron; Mitochondria; Mitochondrial Proteins; Mutation; Protein Transport; Quinazolines | 2010 |
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
Topics: Blotting, Western; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor beta; Gefitinib; Humans; Immunoprecipitation; Mesothelioma; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference | 2010 |
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Protein Binding; Quinazolines; Signal Transduction | 2011 |
Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Genes, ras; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Phosphorylation; Quinazolines; ras Proteins; Vulvar Neoplasms | 2011 |
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Membrane Proteins; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Iodine Radioisotopes; Protein Binding; Protein Multimerization; Quinazolines | 2011 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2012 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth.
Topics: Amino Acid Motifs; Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Peptide Fragments; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Serine; Tandem Mass Spectrometry; Tyrosine | 2012 |
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Topics: Animals; Benzamides; Benzimidazoles; Case-Control Studies; Crk-Associated Substrate Protein; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Mice; Monocrotaline; Myocytes, Smooth Muscle; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Quinazolines; Quinolones; Rats; Signal Transduction | 2012 |
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Quinazolines; Signal Transduction | 2012 |
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction | 2012 |
Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Topics: Animals; Binding Sites; Blotting, Western; Cell Line; Cross-Linking Reagents; Disulfides; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Microscopy, Electron; Mutation; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines | 2012 |
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Reproducibility of Results | 2012 |
Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Disease-Free Survival; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Integrins; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Multivariate Analysis; Neoplasm Transplantation; Phosphoproteins; Phosphorylation; Proportional Hazards Models; Protein Processing, Post-Translational; Quinazolines; Receptor Cross-Talk; Retrospective Studies; RNA, Small Interfering; Signal Transduction | 2012 |
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals.
Topics: Benzamides; Cell Line; Cell Proliferation; Diphenylamine; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Microscopy, Fluorescence; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; S Phase Cell Cycle Checkpoints; Time-Lapse Imaging | 2013 |
Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Topics: Cadherins; Cell Communication; Cell Line, Tumor; Cytoskeleton; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction | 2013 |
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; MAP Kinase Signaling System; Mutation; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Thyroid Neoplasms | 2013 |
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Male; Motor Activity; Quinazolines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 2013 |
Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cross-Linking Reagents; Dimerization; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Iodine Radioisotopes; Isotope Labeling; Panitumumab; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
EpCAM expression in the prostate cancer makes the difference in the response to growth factors.
Topics: AMP-Activated Protein Kinases; Antigens, Neoplasm; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cell Adhesion Molecule; ErbB Receptors; Gefitinib; Humans; Large Neutral Amino Acid-Transporter 1; Male; Neoplastic Stem Cells; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Microenvironment | 2014 |
EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Dynamins; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Hydrazones; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; rab GTP-Binding Proteins; Signal Transduction | 2014 |
Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway.
Topics: Cell Line; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibrinogen; Gefitinib; Humans; Neoplasm Proteins; Phosphorylation; Quinazolines; Recombinant Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcriptional Activation | 2014 |
An in vitro one-dimensional assay to study growth factor-regulated tumor cell-macrophage interaction.
Topics: Animals; Biological Assay; Cell Communication; Cell Line, Tumor; Cell Movement; Coculture Techniques; Collagen Type I; Epidermal Growth Factor; Extracellular Matrix; Female; Fibronectins; Gefitinib; Humans; Macrophages; Mammary Glands, Human; Mice; Molecular Imaging; Quinazolines; Signal Transduction; Time-Lapse Imaging; Tyrphostins | 2014 |
Plasticity of mammary cell boundaries governed by EGF and actin remodeling.
Topics: Actin Cytoskeleton; Actins; Cadherins; Cell Differentiation; Cell Line; Desmosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Shear Strength; Signal Transduction | 2014 |
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Topics: Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; RNA, Messenger; Signal Transduction; src-Family Kinases | 2014 |
EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Topics: Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Monensin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sorting Nexins | 2015 |
TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways.
Topics: Animals; Apoptosis; Atrophy; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interferon-gamma; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parenteral Nutrition, Total; Quinazolines; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; HEK293 Cells; Humans; Lipoylation; Mass Spectrometry; Mice; Mutation; NIH 3T3 Cells; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proteolysis; Quinazolines; RNA Interference; Signal Transduction; Structure-Activity Relationship; Transfection | 2016 |
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Plicamycin; Quinazolines; Signal Transduction; Sp1 Transcription Factor | 2016 |
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Topics: Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-17; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2016 |
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; beta-Transducin Repeat-Containing Proteins; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; Glycogen Synthase Kinase 3 beta; Glycosylation; Humans; Immunologic Surveillance; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Phosphorylation; Programmed Cell Death 1 Receptor; Protein Stability; Quinazolines; T-Lymphocytes; Tumor Escape; Ubiquitination; Xenograft Model Antitumor Assays | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
Gefitinib enhances radiotherapeutic effects of
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution | 2017 |
Exosome production and its regulation of EGFR during wound healing in renal tubular cells.
Topics: Aniline Compounds; Animals; Benzylidene Compounds; Cell Line; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Exosomes; Gefitinib; Kidney Tubules; Mice; Polyenes; Polyunsaturated Alkamides; Quinazolines; Signal Transduction; Time Factors; Wound Healing | 2017 |
Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Topics: Aminolevulinic Acid; Astrocytes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Gene Expression; Glioblastoma; Heme Oxygenase-1; Humans; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2017 |
LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
Topics: Adenoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Down-Regulation; Drug Synergism; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Wnt Signaling Pathway | 2018 |
Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Topics: Antineoplastic Agents; Apoptosis; beta-D-Galactoside alpha 2-6-Sialyltransferase; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Proteomics; Quinazolines; Sialyltransferases; Signal Transduction | 2018 |
Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Ligands; Transforming Growth Factor alpha | 2018 |
Exposure to EGF and 17β‑estradiol irreversibly affects the proliferation and transformation of MCF7 cells but is not sufficient to promote tumor growth in a xenograft mouse model upon withdrawal of exposure.
Topics: Animals; Benzamides; Carcinogenesis; Cell Proliferation; Cell Transformation, Neoplastic; Dioxoles; Epidermal Growth Factor; Estradiol; Female; Gefitinib; Humans; MCF-7 Cells; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Phenotype; Quinazolines; Spheroids, Cellular; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |
Astragaloside VI Promotes Neural Stem Cell Proliferation and Enhances Neurological Function Recovery in Transient Cerebral Ischemic Injury via Activating EGFR/MAPK Signaling Cascades.
Topics: Animals; Astrocytes; Brain Ischemia; Cell Differentiation; Cell Proliferation; Cells, Cultured; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gefitinib; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Memory; Motor Activity; Neural Stem Cells; Neurogenesis; Rats, Sprague-Dawley; Recovery of Function; Saponins; Spheroids, Cellular; Triterpenes | 2019 |
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; STAT1 Transcription Factor | 2018 |
Cnnm4 deficiency suppresses Ca
Topics: Animals; Calcium Signaling; Cation Transport Proteins; Cell Proliferation; Colon; Colonic Neoplasms; Epidermal Growth Factor; Epithelium; Female; Gefitinib; Magnesium; Male; Mice, Mutant Strains; Organ Culture Techniques; TRPV Cation Channels | 2019 |
PPARδ is a regulator of autophagy by its phosphorylation.
Topics: Autophagy; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; Humans; Microtubule-Associated Proteins; Mutation; Phosphorylation; PPAR delta; Protein Binding; Protein Kinase Inhibitors; Tyrosine | 2020 |
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent.
Topics: Animals; Antineoplastic Agents; Epidermal Growth Factor; Fluorescence; Gefitinib; Genes, erbB-2; Mice; NIH 3T3 Cells | 2021 |
Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
Topics: Antineoplastic Agents; Calcium Signaling; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Estrenes; Gefitinib; Humans; Lung Neoplasms; NFATC Transcription Factors; Pyrrolidinones; Type C Phospholipases | 2020 |
Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Movement; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Integrin alpha5beta1; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering | 2021 |
Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling.
Topics: Adult; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Placenta; Placenta Growth Factor; Pre-Eclampsia; Pregnancy; Protein Kinase Inhibitors; Signal Transduction; Trophoblasts | 2021 |
Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells.
Topics: Cell Line, Tumor; Dynamin II; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Low Density Lipoprotein Receptor-Related Protein-1; rab5 GTP-Binding Proteins; Spheroids, Cellular | 2021 |
Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes.
Topics: Chemokines; Epidermal Growth Factor; ErbB Receptors; Fatty Acids; Gefitinib; Humans; Hyaluronic Acid; Keratinocytes; Ligands; Lipids; Protein Kinase Inhibitors; RNA, Messenger; Tumor Necrosis Factor-alpha | 2022 |
Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Peptides; Protein Kinase Inhibitors; Receptors, Progesterone | 2022 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
New quinazolinone-based derivatives as DHFR/EGFR-TK inhibitors: Synthesis, molecular modeling simulations, and anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Folic Acid Antagonists; Gefitinib; Molecular Structure; Protein-Tyrosine Kinases; Quinazolinones; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2023 |